The Precision Peptide Genetic Test ($99) identifies 150+ genetic insights across 14 metabolic pathways, focusing on four key variants: GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313
Despite positive preclinical outcomes, Dapiglutides safety and efficacy had not previously been validated in patients with obesity
While researchers primarily use GLP-1 antagonists for other medical purposes, they continue to explore their potential in metabolism and weight management
Research demonstrates that GLP-1 activation also affects reward pathways in the brain, decreasing the pleasure derived from food consumption
However, other studies involving people with early Alzheimer's or mild cognitive impairment have yielded negative results: One published last year showed no connection between semaglutide and a slowing of cognitive decline
It might be more accurate to say that GLP-1RAs are one especially potent lever that we can use to address the biological underpinnings of obesity, if not the only one available
.webp)
